University of Turin

Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees

Retrieved on: 
Martedì, Febbraio 20, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Genetics, Breast cancer, Woman, Outline, MIA, Neoplasm, Melanoma Institute Australia, European Institute, University, PABC, University of Sydney, Liquid biopsy, NGS, European Journal, Biomarker, Royal Prince Alfred Hospital, Medicine, Patient, University of Turin, GeneXus, Aspirated consonant, Thermo Fisher Scientific, Diagnosis, Melanoma, TKI, Medical imaging

Today, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant , recognizing research from the Melanoma Institute Australia, the University of Turin in Italy and Atrium Health Wake Forest Baptist Medical Center.

Key Points: 
  • Today, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant , recognizing research from the Melanoma Institute Australia, the University of Turin in Italy and Atrium Health Wake Forest Baptist Medical Center.
  • Since its introduction in 2020, the Oncomine Clinical Research Grant program has provided up to $200,000 in reagents and general funding for 22 unique research projects conducted by independent clinical research teams.
  • “The Oncomine Clinical Research Grant program provides us the opportunity to support emerging research projects and their goal of delivering on the promise of precision oncology through the democratization of NGS technology,” said Jose Luis Costa, Ph.D., global director, scientific affairs, clinical next-generation sequencing and oncology, Thermo Fisher Scientific.
  • In late 2023, Oncomine Clinical Research Grant recipients had the opportunity to attend a closed Oncomine Scientific Gala to share their research with the wider pharmaceutical community and showcase the results of their studies and the impact NGS testing can have on oncology research and patient care.

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

Retrieved on: 
Lunedì, Dicembre 11, 2023
Isatuximab, ASCT, ITT, Associate, Bone marrow, EMN, MRD, Young, Multiple myeloma, Society, University of Turin, Lenalidomide, Odds ratio, ASH, University, Dexamethasone, NCAA University Division, AOU, Cell, Patient, Carfilzomib

The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (MM).

Key Points: 
  • The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (MM).
  • The respective rates of MRD negativity at sensitivity of 10-6 were 67% versus 48% (OR 1.93; p=0.006).
  • There was a statistically significant difference in MRD negativity rates after induction with Sarclisa in combination with KRd versus KRd (10-5: 45% versus 26%, p
  • Effective front-line treatment is critical for newly diagnosed patients, because achieving undetectable levels of disease early in the treatment journey may lead to better long-term outcomes.

Cboe Announces Winners of the Options Institute S&P Dow Jones Indices Dispersion Research Grant

Retrieved on: 
Giovedì, Agosto 3, 2023
S&P, Cboe Global Markets, University, Mathematics, Center for Financial Studies, Journal of Financial Economics, VIX, Capital market, Fear, Risk management, The Journal of Finance, MBA, Goethe University Frankfurt, Research, Tail, S&P Dow Jones Indices, Assistant, Financial economics, S, Journal, Journal of Monetary Economics, PhD in management, INSEAD, University of Mannheim Business School, Monetary economics, University of Turin, Management, Knowledge, Collegio Carlo Alberto, Frankfurt School, Economics, CBOE, Business mathematics, Pharmaceutical industry, Security (finance)

The Options Institute Research Grant Program aims to support research that helps catalyze the advancement of derivatives usage and financial exchange marketplace structures.

Key Points: 
  • The Options Institute Research Grant Program aims to support research that helps catalyze the advancement of derivatives usage and financial exchange marketplace structures.
  • As the winners of this grant, sponsored by S&P DJI, Dr. Schoenleber and Dr. Vilkov will study the economics behind option-implied factor dispersion.
  • Significantly, this research is expected to complement the planned launch of the Cboe S&P 500 Dispersion Index , a new volatility-related index jointly created by Cboe and S&P DJI.
  • Cboe has been providing best-in-class investor education through the Options Institute, teaching the responsible use of options and trading strategies for more than 35 years.

Alentis Therapeutics Appoints Luca Santarelli as Chairperson

Retrieved on: 
Giovedì, Giugno 29, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Columbia University, Santarelli, University, Gilles Tordjman, Ironwood Pharmaceuticals, Roche, Cancer, Combined internal medicine and psychiatry residency, Fibrosis, Rare, MD, University of Turin, Pleasure, Biology, Research, Pfizer, Chair, Pharmaceutical industry, Management, Neuroscience, Ophthalmology

Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors.

Key Points: 
  • Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors.
  • Rafaèle Tordjman, former chair of Alentis, will remain on Alentis’ board.
  • His experience as a serial biotech entrepreneur and Alentis board member since 2021 are of great value to our board and company,” said Dr. Roberto Iacone, Chief Executive Officer of Alentis.
  • I look forward to continuing my work as a board member and further supporting the company on its journey.”
    Luca Santarelli, MD, has served as member on Alentis’ board since 2021.

Wrike Teams Up With Unito To Bring Miro Integration To Users

Retrieved on: 
Giovedì, Febbraio 16, 2023
Networks, Data Management, Apps, Applications, Technology, Software, Dark, Organization, GitHub, Bitbucket, Videotelephony, Airtable, Microsoft, Ideation, Salesforce, HubSpot, University of Turin, Jira, Google Sheets, Darkness, Partnership, Azure DevOps, Google Calendar, GitLab, Microsoft Excel, Zendesk, Industrial design, Online shopping, Mobile phone, Wrike

This partnership unlocks greater collaboration capabilities for Wrike users that rely on Miro to capture their creative thinking and, previously, had to manually transfer ideas into Wrike for execution or to share with broader teams.

Key Points: 
  • This partnership unlocks greater collaboration capabilities for Wrike users that rely on Miro to capture their creative thinking and, previously, had to manually transfer ideas into Wrike for execution or to share with broader teams.
  • It also helps break down silos between cross-functional teams that collaborate on projects but may not all be Miro users.
  • “Partnering with Wrike allows Miro users to convert their creative thinking into actionable tasks, shortening the timeline from ideation to implementation.
  • For more information about the integration between Miro and Wrike or to request a demo, please visit: https://www.wrike.com/apps/miro/

Centerview Partners Welcomes Fabio Gallia as Senior Advisor

Retrieved on: 
Mercoledì, Gennaio 18, 2023
Banking, Professional Services, Finance, BAM, Brookfield Asset Management, Ukrsibbank BNP Paribas Group, Continental, University, Centerview, Missouri, Senior advisor, Cassa Depositi e Prestiti, Director general, Edison (company), Centerview Partners, NYSE, CDP, BNP Paribas, BNL, Gaul, Executive Committee, University of Turin, Institute for Research in Economics and Business Administration, Sovereign wealth fund, Pleasure, Management, Economics, Accenture

Centerview Partners, a leading independent investment banking advisory firm, announced today that Fabio Gallia has joined the firm as a Senior Advisor based in Paris.

Key Points: 
  • Centerview Partners, a leading independent investment banking advisory firm, announced today that Fabio Gallia has joined the firm as a Senior Advisor based in Paris.
  • Most recently, Gallia served as General Manager of Fincantieri, the world’s leading shipbuilding company with €7 billion of revenue and approximately 20,000 employees.
  • Gallia was senior advisor in Italy for Brookfield Asset Management (NYSE: BAM) and was on the firm’s Board of European Business Heads.
  • Gallia has also served in senior leadership roles at Capitalia Group and Ersel Asset Management.

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Giovedì, Novembre 17, 2022
Marketing, COVID-19, EPIX, Doctor of Philosophy, University of Turin, GSK, Clinical Colorectal Cancer, Alessandra, Food, University, Team, Amgen, Knowledge, Patient, MD, Security (finance), Cesano, Food and Drug Administration Amendments Act of 2007, Ridinilazole, Cancer, Self-signed certificate, Biogen, Risk, Panitumumab, Prostate cancer, Quality of life, SMMT, CMO, Coronavirus, Clinical trial, Medical imaging, Pharmaceutical industry

Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD,has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD,has been appointed to its Board of Directors, effective immediately.
  • Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs, stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • Dr. Cesano currently serves on the board of Puma Biotechnology Inc. (NASDAQ: PBYI), a clinical stage oncology company focused on solid tumors.
  • Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.

Unito Raises $20 Million to Shape the Future of Collaborative Work

Retrieved on: 
Mercoledì, Ottobre 26, 2022
LinkedIn, Yelp, Fiverr, Insurance, Pinterest, CDPQ, Jira, WIRK-TV, Growth, Partner, Software as a service, Organization, Microsoft Excel, CAD, Bessemer Venture Partners, Asana, Twitter, HubSpot, Facebook, Cincinnati Reds, Senior, Partnership, Trello, Initial public offering, Industry, Google Sheets, Salesforce, DocuSign, CEO, Cincinnati, Headache, Foundation, Equity, Chief executive officer, PagerDuty, COVID-19, Zendesk, Solution, Jira (software), Rail transport, Video game, Renewable energy, University of Turin, GitHub, Bóveda, Twilio, Atlassian, Shopify, Teamwork

One Unito customer, Boveda, saves one full work day each week with the integrations, while another, Verivox, automated the painful manual process of migrating 50,000 Jira issues to ClickUp.

Key Points: 
  • One Unito customer, Boveda, saves one full work day each week with the integrations, while another, Verivox, automated the painful manual process of migrating 50,000 Jira issues to ClickUp.
  • "As SaaS tools proliferate, companies are embracing integrations that bring tools together and power the cross-functional teams that are the future of work," said Marc Boscher, co-founder and CEO at Unito.
  • The explosion of SaaS applications, amplified by the shift to remote work amid the COVID-19 pandemic, has transformed the way employees work and organizations spend resources.
  • We look forward to continuing our partnership with Unito as the company pursues new markets and continues shaping the flow of work."

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist's Lab at Major US Cancer Center

Retrieved on: 
Giovedì, Luglio 28, 2022
DNA, University, Immunity, Protein, Genotype, University of Turin, United States Citizenship and Immigration Services, Research, Immune system, Cancer, Applied physics, MMR, Immunotherapy, DNA mismatch repair, Company, MSK, Neoplasm, Patient, Therapy, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry, Vaccine

Building on seminal discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is building a pipeline targeting novel proteins across the DNA mismatch repair ('MMR') pathway.

Key Points: 
  • Building on seminal discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is building a pipeline targeting novel proteins across the DNA mismatch repair ('MMR') pathway.
  • Dr. Matthew Baker, Chief Executive Officer of NeoPhore, stated:"Collaborating with such prominent leaders in the field of applied cancer genetics is a great privilege.
  • Generation of cancer neoantigens in tumours can be exploited by the patients' immune system to overcome natural defence mechanisms in cancer.
  • Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist's Lab at Major US Cancer Center

Retrieved on: 
Giovedì, Luglio 28, 2022
DNA, University, Immunity, Protein, Genotype, University of Turin, United States Citizenship and Immigration Services, Research, Immune system, Cancer, Applied physics, MMR, Immunotherapy, DNA mismatch repair, Company, MSK, Neoplasm, Patient, Therapy, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry, Vaccine

Building on seminal discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is building a pipeline targeting novel proteins across the DNA mismatch repair ('MMR') pathway.

Key Points: 
  • Building on seminal discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is building a pipeline targeting novel proteins across the DNA mismatch repair ('MMR') pathway.
  • Dr. Matthew Baker, Chief Executive Officer of NeoPhore, stated:"Collaborating with such prominent leaders in the field of applied cancer genetics is a great privilege.
  • Generation of cancer neoantigens in tumours can be exploited by the patients' immune system to overcome natural defence mechanisms in cancer.
  • Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.